ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2729

Treatment Patterns, Unmet Need, and Impact of Psoriatic Arthritis on Patient-Reported Outcomes in the United States

Alice Gottlieb1, Jorge Gratacos-Masmitja2, April Armstrong3, Jo Lambert4, Astrid van Tubergen5, Ara Dikranian6, Birol Emir7, Eustratios Bananis8, Tim Smith7, Laraine Aikman9 and Linda Chen7, 1Tufts University School of Medicine, Boston, MA, 2Servicio de Reumatología, Corporació Sanitoria Parc Taulíde Sabadell, Barcelona, Spain, 3Department of Dermatology, University of Southern California, Los Angeles, CA, 4Department of Dermatology, Ghent University Hospital, Ghent, Belgium, 5Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 6San Diego Arthritis Clinic, San Diego, CA, 7Pfizer Inc, New York, NY, 8Pfizer Inc, Collegeville, PA, 9Pfizer Ltd, Walton Oaks, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: cross-sectional studies, data analysis and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Session Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: This non-interventional, cross-sectional descriptive exploratory analysis aimed to characterize patients (pts) with PsA in the 2015 National Health and Wellness Survey (NHWS) and determine the impact of treatment, or no treatment, on pt-reported outcomes (PROs).

Methods: NHWS is a self-administered, web-based, voluntary, confidential questionnaire that used stratified randomized sampling to provide a representative sample of US adults. Respondents who reported PsA diagnosis were grouped by current treatment: advanced pharmacologic therapies (TNF inhibitors, IL-12/23 and IL-17 antagonists, PDE4 inhibitors) ± other drugs; other pharmacologic therapies (conventional synthetic DMARDs, COX2 inhibitors, NSAIDs, glucocorticoids, topical medications); or no current treatment. Short-Form 36 health survey (SF-36), Work Productivity and Activity Index (WPAI), and Patient Health Questionnaire (PHQ)-9) were investigated and summarized descriptively.

Results: Of 97,700 adults who completed the NHWS, 1059 pts reported PsA diagnosis. Of these, 216 reported treatment with advanced therapies, 206 with other therapies, and 637 reported no current treatment. Age and gender were generally balanced between treatment groups. Prior to treatment with advanced or other therapies, ~88–91% had self-reported moderate or severe PsA, and following treatment, ~54–57% reported moderate to severe PsA, which was similar to those reporting no current treatment (~58%; Table 1). SF-36 and PHQ-9 did not show wide variation in scores across treatment groups. WPAI showed that >40% of pts had work-related impairment due to PsA, despite being treated and having mild to moderate disease (Table 2).

Conclusion: We found that ~60% of pts who reported PsA diagnosis reported no current treatment. Regardless of treatment group, pts reported >20% work loss and >40% work impairment. Among pts treated with advanced and other therapies, >50% reported moderate to severe PsA, suggesting the need for additional therapies and overall better management of PsA to reduce disease activity and improve quality of life. A limitation of this analysis is that pts self-reported PsA diagnosis, and results may differ from pts having physician-reported PsA diagnosis. Further statistical analysis is needed to determine differences between groups and correlation to other health indicators.  


Disclosure: A. Gottlieb, Astellas, Akros, Centocor (Janssen), Celgene, BSM, Beiersdorf Inc, Abbott Labs (AbbVie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd, Pfizer Inc, Canfite, Eli Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, Glaxo Smi, 5,Centocor (Janssen), Amgen, Abbott (AbbVie), Novartis, Celgene, Pfizer Inc, Eli Lilly, Coronado, LeviaMerck, Xenoport, Dermira, Baxalta, 2; J. Gratacos-Masmitja, None; A. Armstrong, Amgen, AbbVie, Janssen, Eli Lilly, 2,Janssen, Pfizer Inc, Celgene, Merck, Eli Lilly, 5,Janssen, Pfizer Inc, Celgene, Merck, Eli Lilly, 6,AbbVie, 8; J. Lambert, None; A. van Tubergen, None; A. Dikranian, Pfizer Inc, AbbVie, 5,Pfizer Inc, Abbvie, 8; B. Emir, Pfizer Inc, 1,Pfizer Inc, 3; E. Bananis, Pfizer Inc, 1,Pfizer Inc, 3; T. Smith, Pfizer Inc, 1,Pfizer Inc, 3; L. Aikman, Pfizer Inc, 1,Pfizer Inc, 3; L. Chen, Pfizer Inc, 1,Paizer Inc, 3.

To cite this abstract in AMA style:

Gottlieb A, Gratacos-Masmitja J, Armstrong A, Lambert J, van Tubergen A, Dikranian A, Emir B, Bananis E, Smith T, Aikman L, Chen L. Treatment Patterns, Unmet Need, and Impact of Psoriatic Arthritis on Patient-Reported Outcomes in the United States [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/treatment-patterns-unmet-need-and-impact-of-psoriatic-arthritis-on-patient-reported-outcomes-in-the-united-states/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-patterns-unmet-need-and-impact-of-psoriatic-arthritis-on-patient-reported-outcomes-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences